Marianna Amboni

List of Publications by Year
in descending order

92 papers	4,439 citations	94433 37 h-index	110387 64 g-index
92 all docs	92 docs citations	92 times ranked	5847 citing authors

#	Article	IF	Citations
1	Cognitive contributions to gait and falls: Evidence and implications. Movement Disorders, 2013, 28, 1520-1533.	3.9	390
2	Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism. Human Mutation, 2013, 34, 1208-1215.	2.5	276
3	The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain, 2014, 137, 2731-2742.	7.6	251
4	Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. Parkinsonism and Related Disorders, 2012, 18, 781-787.	2.2	226
5	Resting-state functional connectivity associated with mild cognitive impairment in Parkinsonâ€™s disease. Journal of Neurology, 2015, 262, 425-434.	3.6	175
6	The Heterogeneity of Early Parkinsonâ€™s Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients. PLoS ONE, 2013, 8, e70244.	2.5	150
7	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: AÂlongitudinal prospective study. Parkinsonism and Related Disorders, 2015, 21, 1219-1226.	2.2	113
8	Future thinking in Parkinson's disease: An executive function?. Neuropsychologia, 2012, 50, 1494-1501.	1.6	108
9	Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. Parkinsonism and Related Disorders, 2015, 21, 489-493.	2.2	97
10	Hearing impairment in Parkinson's disease: Expanding the nonmotor phenotype. Movement Disorders, 2012, 27, 1530-1535.	3.9	93
11	Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment. Lancet Neurology, The, 2016, 15, 1063-1074.	10.2	86
12	Ropinirole as a Treatment of Restless Legs Syndrome in Patients on Chronic Hemodialysis. Clinical Neuropharmacology, 2004, 27, 178-181.	0.7	84
13	A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Movement Disorders, 2007, 22, 2418-2425.	3.9	84
14	Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. Parkinsonism and Related Disorders, 2012, 18, 1034-1038.	2.2	83
15	Gender differences in non-motor symptoms in early, drug naÃ¯ve Parkinsonâ€™s disease. Journal of Neurology, 2013, 260, 2849-2855.	3.6	83
16	<scp>GBAâ€Related</scp> Parkinson's Disease: Dissection of Genotypeâ€“Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	3.9	83
17	Cortical thickness changes in patients with Parkinson's disease and impulse control disorders. Parkinsonism and Related Disorders, 2016, 24, 119-125.	2.2	76
18	Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion. Movement Disorders, 2011, 26, 1458-1463.	3.9	75

#	Article	IF	Citations
19	Apathy in untreated, de novo patients with Parkinsonâ€™s disease: validation study of Apathy Evaluation Scale. Journal of Neurology, 2014, 261, 2319-2328.	3.6	74
20	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. Sleep, 2016, 39, 405-412.	1.1	73
21	A twoâ€year followâ€up study of executive dysfunctions in Parkinsonian patients with freezing of gait at onâ€state. Movement Disorders, 2010, 25, 800-802.	3.9	71
22	Neuropsychological correlates of theory of mind in patients with early Parkinson's disease. Movement Disorders, 2012, 27, 98-105.	3.9	67
23	Gait patterns in parkinsonian patients with or without mild cognitive impairment. Movement Disorders, 2012, 27, 1536-1543.	3.9	66
24	Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease?. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 276-281.	2.3	64
25	Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. Parkinsonism and Related Disorders, 2016, 28, 137-140.	2.2	62
26	Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. Journal of Neurology, 2012, 259, 1808-1813.	3.6	60
27	Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients. Parkinsonism and Related Disorders, 2014, 20, 850-854.	2.2	60
28	Using gait analysisâ€™ parameters to classify Parkinsonism: A data mining approach. Computer Methods and Programs in Biomedicine, 2019, 180, 105033.	4.7	54
29	Resting-state brain networks in patients with Parkinson's disease and impulse control disorders. Cortex, 2017, 94, 63-72.	2.4	53
30	Parkinsonism and essential tremor in a family with pseudo-dominant inheritance ofPARK2: An FP-CIT SPECT study. Movement Disorders, 2007, 22, 559-563.	3.9	46
31	Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinsonâ€™s disease patients. Journal of Neurology, 2013, 260, 438-444.	3.6	46
32	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naÃ¯ve Parkinsonâ€™s disease. Journal of Neurology, 2013, 260, 1724-1730.	3.6	45
33	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
34	Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 43, 114-117.	2.2	43
35	The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinsonâ€™s disease in Italy. Neurological Sciences, 2014, 35, 379-383.	1.9	42
36	Gender and non motor fluctuations in Parkinson's disease: A prospective study. Parkinsonism and Related Disorders, 2016, 27, 89-92.	2.2	42

#	Article	IF	Citations
37	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. Movement Disorders, 2015, 30, 373-378.	3.9	41
38	Dopamine transporter availability in motor subtypes of de novo drug-naÃ¯ve Parkinsonâ€™s disease. Journal of Neurology, 2014, 261, 2112-2118.	3.6	37
39	Why do some Friedreich's ataxia patients retain tendon reflexes?. Journal of Neurology, 1999, 246, 353-357.	3.6	36
40	Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy. Movement Disorders, 2011, 26, 2578-2580.	3.9	36
41	Lower serum uric acid is associated with mild cognitive impairment in early Parkinsonâ€™s disease: a 4-year follow-up study. Journal of Neural Transmission, 2016, 123, 1399-1402.	2.8	36
42	Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?. Parkinsonism and Related Disorders, 2014, 20, 772-775.	2.2	32
43	Step length predicts executive dysfunction in Parkinsonâ€™s disease: a 3-year prospective study. Journal of Neurology, 2018, 265, 2211-2220.	3.6	32
44	Serum IGF-1 is associated with cognitive functions in early, drug-naÃ¯ve Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0186508.	2.5	30
45	Side of onset does not influence cognition in newly diagnosed untreated Parkinson's disease patients. Parkinsonism and Related Disorders, 2013, 19, 256-259.	2.2	28
46	Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease. Parkinsonism and Related Disorders, 2017, 37, 106-110.	2.2	28
47	Cognitive correlates of â€œpure apathyâ€•in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 53, 101-104.	2.2	27
48	Machine Learning Approaches in Parkinsonâ€™s Disease. Current Medicinal Chemistry, 2021, 28, 6548-6568.	2.4	27
49	Multiple system atrophy is associated with changes in peripheral insulinâ€like growth factor system. Movement Disorders, 2010, 25, 2621-2626.	3.9	25
50	Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinsonâ€™s disease. Neurological Sciences, 2012, 33, 1319-1327.	1.9	25
51	Screening LRRK2 gene mutations in patients with Parkinsonâ€™s disease in Ghana. Journal of Neurology, 2012, 259, 569-570.	3.6	24
52	Caffeine consumption and the 4-year progression of de novo Parkinson's disease. Parkinsonism and Related Disorders, 2016, 32, 116-119.	2.2	24
53	Bisphenol A glucuronidation in patients with Parkinsonâ€™s disease. NeuroToxicology, 2017, 63, 90-96.	3.0	24
54	Interoceptive processing deficit: A behavioral marker for subtyping Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2018, 53, 64-69.	2.2	24

#	Article	IF	Citations
55	Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 8936.	3.3	24
56	Effect of Global Postural Rehabilitation program on spatiotemporal gait parameters of parkinsonian patients: a three-dimensional motion analysis study. Neurological Sciences, 2012, 33, 1337-1343.	1.9	23
57	Short-latency afferent inhibition in patients with Parkinsonâ€™s disease and freezing of gait. Journal of Neural Transmission, 2015, 122, 1533-1540.	2.8	22
58	Assessment of apathy minimising the effect of motor dysfunctions in Parkinsonâ€™s disease: a validation study of the dimensional apathy scale. Quality of Life Research, 2017, 26, 2533-2540.	3.1	22
59	Anxiety in early Parkinson's disease: Validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS). Journal of the Neurological Sciences, 2016, 367, 158-161.	0.6	21
60	Machine learning can detect the presence of Mild cognitive impairment in patients affected by Parkinsonâ€™s Disease. , 2020, , .		20
61	Classifying Different Stages of Parkinsonâ€™s Disease Through Random Forests. IFMBE Proceedings, 2020, , 1155-1162.	0.3	20
62	Quitting smoking: An early non-motor feature of Parkinson's disease?. Parkinsonism and Related Disorders, 2015, 21, 216-220.	2.2	19
63	Music Therapy for Motor and Nonmotor Symptoms of Parkinson's Disease: A Prospective, Randomized, Controlled, Singleâ€Blinded Study. Journal of the American Geriatrics Society, 2016, 64, e36-9.	2.6	16
64	Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages. Scientific Reports, 2021, 11, 9297.	3.3	16
65	Exercise dependence induced by pramipexole in Parkinson's Diseaseâ€”A Case Report. Movement Disorders, 2010, 25, 2893-2894.	3.9	13
66	How does smoking affect olfaction in Parkinson's disease?. Journal of the Neurological Sciences, 2014, 340, 215-217.	0.6	13
67	Parkinsonâ€™s disease in sub-Saharan Africa: step-by-step into the challenge. Neurodegenerative Disease Management, 2011, 1, 193-202.	2.2	11
68	Serum uric acid is associated with apathy in early, drug-naÃ¯ve Parkinsonâ€™s disease. Journal of Neural Transmission, 2016, 123, 371-377.	2.8	9
69	Gait Analysis in Progressive Supranuclear Palsy Phenotypes. Frontiers in Neurology, 2021, 12, 674495.	2.4	8
70	Motor dual task with eyes closed improves postural control in patients with functional motor disorders: A posturographic study. Gait and Posture, 2021, 88, 286-291.	1.4	8
71	Parkinsonâ€™s disease management and impulse control disorders: current state and future perspectives. Expert Review of Neurotherapeutics, 2019, 19, 495-508.	2.8	7
72	Classifying patients affected by Parkinsonâ€™s disease into freezers or non-freezers through machine learning. , 2020, , .		7

#	Article	IF	Citations
73	Vitamin D as a possible biomarker of mild cognitive impairment in parkinsonians. Aging and Mental Health, 2021, 25, 1998-2002.	2.8	7
74	Metabolomics in Parkinson's disease. Advances in Clinical Chemistry, 2021, 104, 107-149.	3.7	7
75	Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study. Frontiers in Neurology, 2021, 12, 711358.	2.4	7
76	Mild Cognitive Impairment Subtypes Are Associated With Peculiar Gait Patterns in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 781480.	3.4	7
77	Pallidal stimulation in atypical pantothenate kinaseâ€associated neurodegeneration: Sixâ€year followâ€up. Movement Disorders, 2014, 29, 276-277.	3.9	6
78	Valproateâ€Induced Generalized Choreoathetosis. Movement Disorders Clinical Practice, 2014, 1, 271-272.	1.5	6
79	Comment on Szewczyk-Krolikowski etÂal.: The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism and Related Disorders, 2014, 20, 1319-1320.	2.2	5
80	Validation of the Italian version of the PSP Quality of Life questionnaire. Neurological Sciences, 2019, 40, 2587-2594.	1.9	5
81	Validation of the Italian version of carersâ€™ quality-of-life questionnaire for parkinsonism (PQoL) Tj ETQq1 1 0.784314 rgBT /Overlock	1.9	5
82	The â€œeye of the tigerâ€•sign in pure akinesia with gait freezing. Neurological Sciences, 2011, 32, 703-705.	1.9	4
83	Prospective memory in Parkinsonâ€™s disease: the role of the motor subtypes. Journal of Neurology, 2019, 266, 2505-2511.	3.6	4
84	Prevalence of heterozygous mutations in Niemann-Pick type C genes in a cohort of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 79, 9-10.	2.2	4
85	Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. Parkinsonism and Related Disorders, 2013, 19, 1143-1148.	2.2	3
86	The role of the motor subtypes on the relationship between anxiety and cognitive dysfunctions in Parkinsonâ€™s disease. Journal of Neural Transmission, 2020, 127, 893-898.	2.8	3
87	Interplay between gait and neuropsychiatric symptoms in Parkinsonâ€™s Disease. European Journal of Translational Myology, 2022, 32, .	1.7	3
88	A quantitative analysis of muscular co-activation on EMG signals in spastic patients treated with Botulinum toxin. , 2020, , .		1
89	Neuropsychological correlates of prospective memory: A comparison between tremor-dominant Parkinsonâ€™s disease and cervical dystonia. Journal of Clinical Neuroscience, 2021, 87, 156-161.	1.5	1
90	Step length predicts executive dysfunction in Parkinsonâ€™s disease: a 3-year prospective study. , 2018, 265, 2211.		1

#	Article	IF	Citations
91	Olfaction in Homozygous and Heterozygous <scp>SYNJ</scp>1 Arg258Gln Mutation Carriers. Movement Disorders Clinical Practice, 2015, 2, 413-416.	1.5	0
92	Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: State of the art 10 years after marketing. Parkinsonism and Related Disorders, 2016, 22, e97-e98.	2.2	0